Drugmaker Hikma's U.S. unit raises medicine prices: Financial Times
Reuters: Health News
NEW YORK (Reuters) - Hikma Pharmaceuticals Plc's U.S. subsidiary has raised the price of a common diarrhea drug by more than 400 percent and is charging more for five other medicines as well, the Financial Times reported on Sunday.
(Reuters) - A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers' blood thinner Xarelto led to severe internal bleeding.
(Reuters Health) - People with chronic low back pain may feel it even more sharply if their spouses are critical and unsupportive of their condition, according to a recent study.
(Reuters Health) - Women with anorexia nervosa or bulimia are up to four times more likely to be convicted of theft - often petty thefts like shoplifting - compared to peers without eating disorders, according to results from a large Swedish study.
BOSTON (Reuters) - Insys Therapeutics Inc has agreed to pay $4.45 million to resolve a lawsuit by Illinois' attorney general claiming it deceptively marketed an addictive fentanyl-based cancer pain drug for off-label uses.
NEW DELHI (Reuters) - The Indian government has threatened Philip Morris International Inc with "punitive action" over the tobacco giant's alleged violation of the country's anti-smoking laws, according to a letter sent to the company by the federal health ministry.
BEIJING (Reuters) - China confirmed a bird flu outbreak at quail farms in the country's southwestern province of Guizhou, according to a Ministry of Agriculture statement on Friday.
CHICAGO (Reuters) - South Korea lifted a ban on imports of U.S. poultry and eggs, the U.S. Department of Agriculture said on Thursday, allowing American farmers to resume sales to the Asian country that suffered an egg shortage caused by its worst-ever bird flu outbreak.
(Reuters) - The U.S. Food and Drug Administration (FDA) said on Thursday it approved Pfizer Inc's rare blood cancer drug, Besponsa, with a boxed warning.
BOSTON (Reuters) - Mylan NV has finalized a $465 million settlement resolving U.S. Justice Department claims it overcharged the government for its EpiPen emergency allergy treatment, which became the center of a firestorm over price increases.
No comments:
Post a Comment